HUTCHMED (HCM)
NASDAQ:HCM
HCM Stock Chart & Stats
$14.15
$0.15(1.02%)
At close: 4:00 PM EST
$14.15
$0.15(1.02%)
Day’s Range― - ―
52-Week Range$11.51 - $19.50
Previous CloseN/A
Volume23.53K
Average Volume (3M)48.41K
Market Cap
$2.45B
Enterprise Value$2.39B
Total Cash (Recent Filing)$1.36B
Total Debt (Recent Filing)$93.44M
Price to Earnings (P/E)5.0
Beta0.42
Next Earnings
Aug 03, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding174,465,530
10 Day Avg. Volume34,563
30 Day Avg. Volume48,412
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.85
Price to Sales (P/S)4.16
P/FCF Ratio-28.96
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.97
Enterprise Value/Gross Profit44.47
Enterprise Value/Ebitda-319.18
Forecast
1Y Price Target
$20.00Price Target Upside41.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.31
Revenue Forecast (FY)$637.63M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetHutchmed's very low debt-to-equity (~0.08) provides durable financial flexibility to support multi-year R&D and late-stage trials. Low leverage reduces interest costs and refinancing risk, enabling the company to fund development or strategic collaborations without near-term balance-sheet strain.
Late-stage Clinical Validation & ApprovalPublication of the SACHI Phase III in The Lancet and the June 2025 China approval of the savolitinib+osimertinib combination materially de-risks that program. Clinical validation and regulatory approval support sustainable commercialization, strengthen partner ties (AstraZeneca) and enhance the firm's long-term franchise value.
Reimbursement And Commercial Access In ChinaRenewal of the NHSA contract and continued inclusion of key drugs on China's National Reimbursement Drug List secures payer coverage. Durable reimbursement improves market access, supports steady demand and revenue predictability in China—a critical commercial market for sustaining product sales and reinvestment.
Bears Say
Negative Cash GenerationMaterial negative operating and free cash flow in 2025 indicates the business is consuming cash rather than generating it. Persistent cash burn increases reliance on external financing or partner milestones, raising execution risk for multi-year trials and potentially forcing trade-offs between R&D, commercialization and capital preservation.
Weakening Revenue & Operating ProfitabilityA year-over-year revenue decline alongside the shift to negative EBITDA/EBIT signals deteriorating core operations and margin pressure. This undermines the company's ability to self-fund growth, reduces reinvestment capacity into late-stage programs, and suggests the commercial model faces durability challenges absent operational fixes.
Earnings Quality ConcernsExceptional net income in 2025 that contrasts with operating losses implies reliance on non-recurring or non-operating items. That reduces earnings predictability and investor confidence, and means reported profits may not translate into sustainable cash flows to underwrite R&D or commercialization over the coming quarters.
HUTCHMED News
HCM FAQ
What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was $11.51 and its highest was $19.50 in the past 12 months.
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is $2.45B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Aug 03, 2026 which is in 129 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Mar 05, 2026. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.5 by -$2.49.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 0.11.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,465,530 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of $0.01 in its last earnings report, missing expectations of $2.5. Following the earnings report the stock price went up 1.502%.
Which hedge fund is a major shareholder of HUTCHMED?
Currently, no hedge funds are holding shares in HCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HUTCHMED Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (41.34% Upside)
$20.00 (41.34% Upside)
Hedge Fund Trend
Decreased
By 110.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.03%
12-Months-Change
Fundamentals
Return on Equity
41.91%
Trailing 12-Months
Asset Growth
37.59%
Trailing 12-Months
Company Description
HUTCHMED
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
HCM Company Deck
HCM Earnings Call
Q4 2026
0:00 / 0:00
HCM Stock 12 Month Forecast
Average Price Target
$20.00
▲(41.34% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
0.09% Mutual Funds
0.48% Other Institutional Investors
99.32% Public Companies and
Individual Investors